Key Takeaways
- • U.S. venture fundraising totaled $108.5 billion in the first three quarters of 2026, already well above the $78.3 billion raised for all of 2025, according to PitchBook.
- • The median time between venture funds is on track to fall this year, indicating faster re-up cycles for established managers.
- • First-time venture fund formation and fundraising are both on track to fall steeply to decade lows, according to the primary source.
- • The divergence between aggregate fundraising strength and newcomer weakness highlights a concentration of capital among established firms.
- • Biotech startup Ollin Biosciences agreed to be acquired by Johnson & Johnson for an initial $2.2 billion, per the same Wall Street Journal newsletter.
Summary
The aggregate picture masks a sharp divergence for emerging managers. The Wall Street Journal reports that first-time fund formation and first-time fundraising are both on track to fall steeply, to decade lows. Capital appears concentrated among established platforms, leaving newcomers with limited access to institutional commitments despite the strength of the overall market.
The newsletter also notes that biotech startup Ollin Biosciences agreed to be acquired by Johnson & Johnson for an initial $2.2 billion. The primary source provides limited detail beyond this headline figure.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.